GAINESVILLE, Fla.--(BUSINESS WIRE)--Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, hosted more than 70 shoulder specialists at its recent Shoulder Masters Course in San Francisco, Calif.
Twenty-one presentations highlighted new insights about shoulder arthroplasty, including 11 clinical outcome studies. Attendees included surgeons from seven countries, including the United States, Canada, France, Italy, Brazil, Korea and the United Kingdom.
“The Masters Course in Shoulder Arthroplasty embodies Exactech’s vision to deliver solutions that improve patient outcomes,” said Darin Johnson, Vice President of Marketing for Exactech Extremities and Hip. “Global thought leaders presented data collected over the past 10 years demonstrating the results of the Equinoxe® products. Panel discussions and open questions from the floor put the spotlight on current clinical challenges that will fuel development for the next decade.”
“Exactech set a new standard for medical education with this Shoulder Masters Course,” said Emilie Cheung, MD, Associate Professor of Orthopaedic Surgery at the Stanford University Medical Center. “The clinical outcomes were impressive, and the faculty of experienced orthopaedic surgeons provided insights on ways to deal with tough challenges in the O.R.”
One of the highlighted studies included a retrospective review of patient outcomes and complications for 51 consecutive proximal humerus (upper arm) fractures that were treated with the Equinoxe Fracture Plate. Lead researcher Kenneth Egol, MD, New York University - Hospital for Joint Diseases, presented results showing that the patient’s postoperative flexion and rotation outcomes compare favorably to published reports of other locking plate systems.
David Collins, MD, Arkansas Specialty Orthopaedics/Central Arkansas Veterans Health Care System, presented a large-scale clinical outcome study which demonstrated that patients with scapular notching, an erosion of the scapula (shoulder blade) that can occur with reverse shoulder arthroplasty, experience significantly poorer outcomes and a greater complication rate than patients without scapular notching at a similar average postoperative follow-up.
Additionally, Felix (Buddy) Savoie, MD, Tulane University School of Medicine, discussed a minimally-invasive, tissue preserving approach which provides adequate exposure for shoulder replacement surgery and provides a decreased risk of postoperative failure (rupture or atrophy) of the subscapularis tendon.
The course’s 15 faculty members included Greg Bauer, MD; Emilie Cheung, MD; David Collins, MD; Lynn Crosby, MD; Kenneth Egol, MD; Pierre-Henri Flurin, MD; Richard Friedman, MD; Sean Grey, MD; Richard Jones, MD; Curtis Noel, MD; Howard Routman, DO; Felix (Buddy) Savoie, MD; Ryan Simovitch, MD; Thomas Wright, MD; and Joseph Zuckerman, MD. The proceedings from this course will be published in the Bulletin of the Hospital for Joint Diseases at the end of this year.
The scope of the studies referenced is specific to Equinoxe implants and performed by Exactech consultants.
About Equinoxe® Shoulder
Exactech’s Equinoxe Shoulder System has been one of the fastest growing systems since its introduction 10 years ago. No matter what challenges a surgeon may face, the system offers true “reversatility,” designed to enable surgeons to convert from either a primary shoulder or fracture hemi to a reverse shoulder without stem removal. It also is the only system that offers augmented glenoid solutions for both the anatomic and reverse.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.